Discovery

DirectEmployers Honored as Bronze Stevie® Award Winner for Customer Service Department of the Year in 2024 Sales & Customer Service Awards

Retrieved on: 
Tuesday, April 16, 2024
Professional Services, Human Resources, Gold standard, Bronze, Heart, Customer service, Stevie Awards, Digital, Employment, CSAT, Discovery, Customer, Multimedia, Gold, Organization, Growth, Sales

DirectEmployers Association , known as the "Gold Standard" in OFCCP compliance and diversity outreach solutions by over 1,050+ global employers, was named the winner of a Bronze Stevie® Award in the Customer Service Department of the Year category in The 18th Annual Stevie Awards for Sales & Customer Service .

Key Points: 
  • DirectEmployers Association , known as the "Gold Standard" in OFCCP compliance and diversity outreach solutions by over 1,050+ global employers, was named the winner of a Bronze Stevie® Award in the Customer Service Department of the Year category in The 18th Annual Stevie Awards for Sales & Customer Service .
  • View the full release here: https://www.businesswire.com/news/home/20240416668542/en/
    DirectEmployers Member Engagement Team takes home a Bronze Stevie Award in the competition's Customer Service Department of the Year.
  • "We are honored to be recognized again by the Stevie® Awards," said Kate Larrabee, DirectEmployers Manager of Member Engagement.
  • Further details about the Stevie Awards for Sales & Customer Service are available at www.stevieawards.com/sales .

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

Retrieved on: 
Thursday, April 25, 2024
Dai, ONO, PPI, Drug discovery, PRISM, Patient, Discovery, History, Pharmaceutical industry

TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. ("Ono ").

Key Points: 
  • Under the terms of the agreement, Ono and PRISM will jointly create a development candidate for Ono's oncology target using PepMetics® technology.
  • Upon identification of the development candidate, PRISM will license its rights to Ono for clinical development and commercialization.
  • "We highly appreciate PRISM's PepMetics® technology in PPI drug discovery", said Seishi Katsumata, Executive Director, Discovery & Research of Ono.
  • "We are very excited to enter into this collaboration with Ono who has a history of creating innovative drugs.

Anatomy IT Launches Groundbreaking Cybersecurity Solution Suite in Wake of Industry Breach

Retrieved on: 
Wednesday, April 24, 2024
CISO, Modern Healthcare, Discovery, Anatomy, Posture, NIST, Computer, Organization

Costs associated with cybersecurity incidents also continue to climb, reaching an average of $11 million per data breach in 2023, up 53% from 2020.

Key Points: 
  • Costs associated with cybersecurity incidents also continue to climb, reaching an average of $11 million per data breach in 2023, up 53% from 2020.
  • The comprehensive suite of solutions is set to redefine the industry standard for healthcare-specialized data and systems protection.
  • "With our end-to-end Security Solution Suite, care delivery organizations can stay ahead of the curve and mitigate risks effectively, regardless of their size."
  • For more information about Anatomy IT's expanded Security Suite and to schedule a consultation, visit https://anatomyit.com/security-consult/ .

4DDiG Data Recovery Free V10.0.4 Released: Recover Up to 2GB Data for Free

Retrieved on: 
Tuesday, April 16, 2024
AI, Software, MB, Data recovery, Discovery, USB, Algorithm, IOS, Computer data storage

NEW YORK, April 16, 2024 /PRNewswire/ -- Recently, 4DDiG, a leading software company (a unit of Tenorshare), announced the release of 4DDiG Data Recovery Free V10.0.4, which enables Windows users to recover up to 2GB of data at no cost.

Key Points: 
  • NEW YORK, April 16, 2024 /PRNewswire/ -- Recently, 4DDiG, a leading software company (a unit of Tenorshare), announced the release of 4DDiG Data Recovery Free V10.0.4, which enables Windows users to recover up to 2GB of data at no cost.
  • In addition to the generous free data recovery allowance, 4DDiG Data Recovery Free also boasts several other key features.
  • High Recovery Success Rate: 4DDiG Data Recovery Free utilizes advanced algorithms to scan storage devices thoroughly and retrieve lost data effectively.
  • Versatile Data Recovery: Whether it's a computer hard drive, external hard disk, USB drive, SD card, or other storage media, 4DDiG Data Recovery Free supports a wide range of devices, making it versatile for various data recovery scenarios.

Nucleus Security Adds Industry Veterans to Board and Executive Team as Company Scales to Meet Growing Demand

Retrieved on: 
Wednesday, April 10, 2024
Synopsys, Hacker, CMO, SentinelOne, Fortinet, Cisco, Tenable, Knowledge, Risk management, Acquisition, Discovery, Marketing, Growth, Management

SARASOTA, Fla., April 10, 2024 /PRNewswire/ -- Nucleus Security, the leading innovator in enterprise risk-based vulnerability management, today announced the appointment of Jeremiah Grossman to its Board of Directors and Tamir Hardof as Chief Marketing Officer (CMO).

Key Points: 
  • "Jeremiah and Tamir bring decades of experience, knowledge, and leadership in the enterprise security space to Nucleus," said Stephen Carter, co-founder and CEO of Nucleus Security.
  • In addition to his appointment to Nucleus' Board of Directors, he's on the Board for RedShield Security and advisor to several other cybersecurity companies.
  • Nucleus uniquely addresses this problem, leading organizations to mitigate vulnerabilities 10 times faster," said Jeremiah Grossman, Board Member, Nucleus Security.
  • I'm thrilled to join such a talented team," said Tamir Hardof, CMO, of Nucleus Security.

Quanta Presents Preclinical Data for QTX3544, a Potent and Selective G12V-preferring Multi-KRAS Inhibitor, in Late-Breaking Session at Annual AACR Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Discovery, MAPK, Patient, Lung, Doctor of Philosophy, MD, IND, AACR, Therapy, Stomach

RADNOR, Pa. & SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company leading innovative development of direct, oral therapeutics for RAS-driven cancers, announced the presentation of QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ multi-KRAS), in a late-breaking poster presentation session at the American Association of Cancer Research (AACR) Annual Meeting.

Key Points: 
  • QTX3544 demonstrated a favorable preclinical profile, including high selectivity and potent activity against multiple KRAS mutations with preference for the G12V mutation.
  • Additionally, QTX3544 significantly inhibited KRASG12V tumor growth in preclinical animal models and exhibited promising oral bioavailability and pharmacokinetic properties.
  • “We continue to advance our pipeline of candidates against KRAS-driven cancer mutations focusing on the most prevalent drivers, G12D and G12V,” said Perry Nisen, MD, PhD, Chief Executive Officer of Quanta.
  • We look forward to completing IND-enabling studies for QTX3544 this year to support future clinical studies in patients with G12V-mutated solid tumors, a population without targeted treatment options.”
    Data from the presentation are summarized below.

Coherent Loans James Webb Space Telescope Demonstration Mirror to Space Foundation Discovery Center

Retrieved on: 
Monday, April 8, 2024
Discovery, Beryllium, Science, MDT, COHR, Education, Gold, History, Coherence, Senior, STEAM, Mathematics, JWST, Coherent Corp., OLED, Hubble Space Telescope, Engineering

PITTSBURGH, April 08, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a leader in advanced optical systems, announced today an agreement with the Space Foundation Discovery Center , located in Colorado Springs, Colorado, to provide on loan a demonstration mirror developed for the James Webb Space Telescope (JWST).

Key Points: 
  • PITTSBURGH, April 08, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a leader in advanced optical systems, announced today an agreement with the Space Foundation Discovery Center , located in Colorado Springs, Colorado, to provide on loan a demonstration mirror developed for the James Webb Space Telescope (JWST).
  • The Space Foundation Discovery Center focuses on inspiring and educating individuals of all ages about space, science, and technology.
  • “The hexagonal mirrors are not only a testament to the technological expertise behind the James Webb Space Telescope, but also a symbol of the collaborative spirit driving humanity's exploration of the universe,” said Rachel English , Space Foundation Discovery Center senior curator.
  • Attendees are invited to join Coherent and the Discovery Center representatives for this ceremony, which will take place at 4:00 p.m. MDT.

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Wednesday, April 3, 2024
Discovery, Epilepsy, GABAB, Senior, Glutamic acid, Dyskinesia, Glutamate (neurotransmitter), Drug discovery, Partnership, TBI, SIX, Chronic cough, NAM, CHF5, Therapy, DSM-IV codes, Janssen, Safety, ADX71149, Allosteric regulation, Janssen Pharmaceuticals, Dipraglurant, Research fellow, PAM, Pharmaceutical industry

With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.

Key Points: 
  • With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development.
  • In return, Addex will receive CHF5 million and a 20% equity interest in Neurosterix.
  • “The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic,” said Tim Dyer, CEO of Addex.
  • To guide the launch of Neurosterix, Tim Dyer, in addition to his role at Addex, will assume the role of CEO of Neurosterix.

Demand for Bitsight Exposure Management Products Soars by 2x as Cyber Threats Intensify and Regulations Drive Increased Scrutiny

Retrieved on: 
Tuesday, April 9, 2024
Discovery, BearingPoint, KEV, Organization, Risk management, Growth, Risk, CISO, Security, Critical

BOSTON, April 9, 2024 /PRNewswire/ -- Bitsight today announced customer growth of more than 215% for its Enhanced External Attack Surface Management (EASM) and the launch of more than 20 new features for exposure management over the past year. Coupled with the  robust expansion of its Third-Party Risk Management solutions as regulations in Europe intensify, and a growing desire from security leaders to consume contextualized threat insights from Bitsight's Data Solutions feed, the achievements mark key milestones in the company's cyber risk management strategy.

Key Points: 
  • Bitsight External Attack Surface Management and Data Solutions help security and risk leaders identify, prioritize, communicate, and mitigate risk across their digital ecosystem.
  • Over the past 12 months, Bitsight has increased investment in its industry-leading data offerings,  which provide high-value insight into cyber security risks.
  • The expanded coverage and new delivery methods help Bitsight customers more rapidly identify areas of impact and mitigate issues faster.
  • Learn more about Bitsight's exposure management solutions or read the latest KuppingerCole Leadership Compass Report, which names Bitsight as an overall leader, product leader, innovation leader and market leader, here .

Asians in Advertising Breaking Barriers Summit

Retrieved on: 
Tuesday, April 9, 2024
Discovery, Publicis, Partnership, Bias, Carat, Syndrome, Mark Huffam, Senior, Warner Bros., AANHPI, Multimedia, Marketing, Movement, Management

LOS ANGELES, April 9, 2024 /PRNewswire/ -- Asians in Advertising proudly announces the return of its highly anticipated annual Breaking Barriers Summit, scheduled for Friday, May 3, 2024.

Key Points: 
  • LOS ANGELES, April 9, 2024 /PRNewswire/ -- Asians in Advertising proudly announces the return of its highly anticipated annual Breaking Barriers Summit, scheduled for Friday, May 3, 2024.
  • The Breaking Barriers Summit is designed to empower attendees to advance their careers by addressing the unique challenges Asian Americans face in advertising, marketing, and communications.
  • "We're deeply honored to present our third annual Breaking Barriers Summit," expressed Bernice Chao, co-founder of Asians in Advertising.
  • Discovery
    Asians in Advertising aims to develop a community, create opportunities, and elevate Asians to higher leadership positions in the advertising industry.